Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-Met inhibitors with different binding modes: two is better than one.

Cell cycle (Georgetown, Tex.) - 1 May 2008

Dussault Isabelle, Bellon Steven F

Abstract excerpt

Primary and acquired resistance to kinase inhibitors due to pre-existing mutations of the target or to mutations that arise as a result of selection by therapy is now a common theme in cancer patients treated with these drugs. Different classes of inhibitors for the same target have been successful in overcoming, at least temporarily, these resistance mechanisms because of their ability to interact with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Design
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Protein Binding

Share to Protein Kinase Inhibitors

Share to Protein Structure, Tertiary

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 18418040
DOI: 10.4161/cc.7.9.5827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-Met inhibitors with different binding modes: two is better than one.PMID 18418040Read ↗

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Semantic proximity Read ↗

From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.Semantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based DerivativesSemantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.Semantic proximity Read ↗

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.Semantic proximity Read ↗

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.Semantic proximity Read ↗

Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studies.Semantic proximity Read ↗

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.